cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sangamo Therapeutics Inc
21 own
25 watching
Current Price
$1.23
$0.32
(35.15%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
126.24M
52-Week High
52-Week High
1.48000
52-Week Low
52-Week Low
0.29000
Average Volume
Average Volume
65.18M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization126.24M
icon52-Week High1.48000
icon52-Week Low0.29000
iconAverage Volume65.18M
iconDividend Yield--
iconP/E Ratio--
What does the Sangamo Therapeutics Inc do?
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Read More
How much money does Sangamo Therapeutics Inc make?
News & Events about Sangamo Therapeutics Inc.
Business Wire
2years ago
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest...
Zolmax
2years ago
DekaBank Deutsche Girozentrale boosted its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO Get Rating) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,900 shares of the biopharmaceutical ...
Ticker Report
2years ago
Equities analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO Get Rating) will post ($0.32) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sangamo Therapeutics earnings. The lowest ...
PR Newswire
2years ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty...
Zolmax
2years ago
StockNews.com began coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a hold rating on the biopharmaceutical companys stock. Other equities analysts have also recently ...
Frequently Asked Questions
Frequently Asked Questions
What is Sangamo Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Sangamo Therapeutics Inc shares?
plus_minus_icon
How can I buy Sangamo Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Sangamo Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Sangamo Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Sangamo Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Sangamo Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Sangamo Therapeutics Inc?
plus_minus_icon
What percentage is Sangamo Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Sangamo Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.23
$0.32
(35.15%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Mesoblast
Mesoblast
$9.43
$-0.22 (-2.28 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$5.65
$0.20 (3.67 %)
Gevo Inc
Gevo Inc
$3.02
$-0.27 (-8.21 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.80
$-0.04 (-2.17 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mesoblast
Mesoblast
$9.43
$-0.22 (-2.28 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$5.65
$0.20 (3.67 %)
Gevo Inc
Gevo Inc
$3.02
$-0.27 (-8.21 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.80
$-0.04 (-2.17 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00